Anne Wojcicki

	Personal details
Born	Anne Wojcicki; 1973/7/28 (age 52); 🇺🇸 San Mateo County, California, United States
Nationality	🇺🇸 American
Citizenship	🇺🇸 American
Languages	🇺🇸 English
Education	Yale University (BS)
Spouse	Sergey Brin (m. 2007-2015)
	Career details
Occupation	Entrepreneur, biologist
Title	Co-founder and CEO of 23andMe
Net worth	US$400 million (December 2025)

Anne E. Wojcicki (born July 28, 1973) is an American entrepreneur and the co-founder and Chief Executive Officer of 23andMe, a personal genomics company that pioneered direct-to-consumer DNA testing. Under Wojcicki's leadership, 23andMe has analyzed the genetic data of over 12 million customers, creating one of the world's largest genetic databases and contributing to groundbreaking research on heredity, disease susceptibility, and human ancestry. Wojcicki was married to Sergey Brin, co-founder of Google, from 2007 to 2015, and their relationship intertwined the fates of two major technology companies. Following her divorce, Wojcicki focused on expanding 23andMe's mission beyond consumer testing into pharmaceutical drug discovery, though the company has faced significant challenges including FDA regulatory battles and financial struggles. Her net worth is estimated at $800 million.

Early Life and Family

Anne E. Wojcicki was born on July 28, 1973, on the Stanford University campus in Palo Alto, California, to Stanley Wojcicki, a Polish-American physics professor at Stanford, and Esther Wojcicki, an American educator who pioneered the use of media literacy in education. Growing up in Silicon Valley's intellectual epicenter, Anne was immersed in an environment valuing education, innovation, and achievement.

Anne's family background is remarkable for its accomplished members. Her older sister, Susan Wojcicki, served as CEO of YouTube from 2014 until 2023 and was one of Google's earliest employees, making the Wojcicki sisters among the most powerful women in technology. Her younger sister, Janet Wojcicki, was a prominent anthropologist and epidemiologist at the University of California, San Francisco. Tragically, Susan Wojcicki died in August 2024 from lung cancer at age 56.

The Wojcicki household emphasized intellectual curiosity, social responsibility, and independent thinking. Anne's mother, Esther, was particularly influential, having created a pioneering journalism program at Palo Alto High School that produced graduates including Steve Jobs' biographer Walter Isaacson. This environment shaped Anne's belief that technology and science could democratize information and empower individuals.

Education

Wojcicki attended Yale University, where she earned a Bachelor of Science degree in biology in 1996. At Yale, she focused on molecular biology and developed a particular interest in the intersection of biology and data - how large-scale biological information could reveal patterns invisible at the individual level.

After graduating, Wojcicki initially pursued a career on Wall Street, working as a healthcare consultant and investment analyst at investment firms including Passport Capital and Investor AB. She focused on biotechnology and healthcare companies, gaining insight into the pharmaceutical industry's economics and the healthcare system's inefficiencies. However, she found the work unfulfilling, feeling disconnected from direct impact on people's health.

This Wall Street experience, while brief, proved valuable. It taught Wojcicki how to analyze business models, raise capital, and navigate regulatory environments - skills essential for building 23andMe.

Career

Founding 23andMe (2006)

In 2006, Wojcicki co-founded 23andMe with Linda Avey and Paul Cusenza, driven by a vision to make genetic information accessible and actionable for individuals. The company's name derives from the 23 pairs of chromosomes in normal human cells.

Wojcicki's motivation was both personal and ideological. She believed the traditional healthcare system was reactive rather than proactive, treating diseases after they manifested rather than preventing them through early detection and lifestyle modification. She saw genetic testing as a tool for empowerment, allowing individuals to understand their predispositions and make informed health decisions.

Initially, the company focused on ancestry and traits testing, providing customers with information about their ethnic background, inherited characteristics, and genetic connections to distant relatives. The service required customers to provide a saliva sample, which 23andMe would analyze to generate reports on ancestry composition, genetic relatives, inherited traits, and - controversially - health predispositions including disease risks.

Growth and Google Connection

23andMe's early growth was aided significantly by Wojcicki's marriage to Sergey Brin, whom she married in May 2007 in an informal ceremony in the Bahamas. Brin provided critical early funding for 23andMe, and Google Ventures invested $3.9 million in the company's Series A funding round in 2007. This connection to one of the world's most powerful tech companies provided 23andMe with resources, publicity, and credibility that most biotech startups could only dream of.

However, the Google connection also generated skepticism. Critics questioned whether 23andMe was a legitimate scientific enterprise or essentially a vanity project bankrolled by Brin's wealth. These suspicions intensified when it emerged that 23andMe's research into Parkinson's disease - a condition Brin carries a genetic marker for - might be motivated by personal interest.

FDA Battle (2013-2015)

23andMe's most significant crisis came in November 2013 when the Food and Drug Administration (FDA) ordered the company to immediately stop marketing its health-related genetic tests. The FDA argued that 23andMe's tests were medical devices requiring regulatory approval, and that the company had failed to demonstrate the tests' accuracy and clinical validity.

The FDA's concern centered on the risk of customers making major health decisions based on potentially inaccurate or misinterpreted genetic information. For example, if a test incorrectly indicated someone had a BRCA gene mutation (dramatically increasing breast cancer risk), they might undergo preventive mastectomy unnecessarily. Conversely, false negatives could provide false reassurance.

The FDA ban was devastating. 23andMe had to cease providing health-related reports to new customers (though existing customers retained access to their results), effectively gutting the company's value proposition. Many observers predicted 23andMe would not survive.

Wojcicki's response demonstrated resilience and strategic thinking. Rather than fighting the FDA through litigation, she engaged in extensive negotiation and cooperation. 23andMe conducted additional validation studies, refined its reporting methods, and worked systematically through FDA concerns. In February 2015, the FDA granted 23andMe authorization to market a carrier screening test for Bloom syndrome. This partial approval opened the door for additional authorizations.

By April 2017, 23andMe received FDA authorization to provide reports on genetic health risks for 10 diseases including Parkinson's, Alzheimer's, and celiac disease - a major victory demonstrating that direct-to-consumer genetic testing could meet regulatory standards.

Pivot to Drug Discovery

Following the FDA battle, Wojcicki pivoted 23andMe's strategy significantly. While continuing consumer genetic testing, the company increasingly focused on using its database for pharmaceutical research and drug discovery. With millions of customers consenting to research use of their genetic data, 23andMe possessed an unprecedented resource for identifying genetic associations with diseases.

In 2015, 23andMe established a therapeutics division to develop drugs based on insights from its genetic database. The company signed major partnerships with pharmaceutical giants including Pfizer, Genentech, and GlaxoSmithKline (which invested $300 million in 23andMe in 2018).

The strategy was promising: traditional drug discovery required expensive clinical trials recruiting thousands of patients; 23andMe had genetic and phenotypic data from millions. This could dramatically accelerate identifying drug targets and patient populations.

However, the pivot also generated controversy. Many customers felt betrayed, arguing they had provided DNA samples for personal genetic information, not to contribute to pharmaceutical company profits. Privacy advocates raised concerns about how genetic data might be used or potentially misused. Wojcicki maintained that customers explicitly consented to research and that 23andMe was using data responsibly to advance medical knowledge.

Financial Challenges and SPAC Merger

Despite its scientific accomplishments, 23andMe struggled financially. The direct-to-consumer genetic testing market proved more limited than initially projected - most people purchase one test and never return. Revenue growth stalled.

In June 2021, 23andMe went public via a Special Purpose Acquisition Company (SPAC) merger at a $3.5 billion valuation. The transaction provided capital for drug development programs.

However, 23andMe's stock performance post-SPAC has been disastrous. As of 2024, the stock trades at a fraction of its initial value, and the company faces potential delisting from NASDAQ due to insufficient stock price. 23andMe has conducted layoffs, closed its therapeutics division, and faces questions about its long-term viability.

In September 2024, Wojcicki announced her intention to take 23andMe private, proposing to buy out public shareholders. This move would allow her to restructure the company away from public market pressures, though it remains uncertain whether she can raise necessary financing.

Personal Life

Marriage to Sergey Brin

Anne Wojcicki met Sergey Brin in the late 1990s through Silicon Valley social circles. The two began dating and married in May 2007 in a casual ceremony in the Bahamas. The wedding was notably informal, with Brin wearing a wetsuit and guests arriving by boat.

The couple had two children together: a son, Benji, born in December 2008, and a daughter, Chloe, born in late 2011. During their marriage, Wojcicki and Brin were considered one of Silicon Valley's power couples, with combined influence spanning search engines, online video, and genetic testing.

However, the marriage experienced difficulties. In August 2013, Wojcicki and Brin separated after Brin had an affair with Amanda Rosenberg, a Google Glass marketing manager. The affair generated significant media attention, particularly given Google's workplace relationship policies and Brin's position.

The divorce was finalized in 2015. Despite the infidelity and publicdivorce, Wojcicki and Brin maintained a reportedly amicable relationship for co-parenting purposes and remained connected through business relationships (Google remained a 23andMe investor).

Post-Divorce Life

Following her divorce, Wojcicki has maintained greater privacy about her personal relationships. She has focused publicly on 23andMe and raising her children. She reportedly dated Alex Rodriguez, the former professional baseball player, in 2016, though the relationship was brief.

Wojcicki has been open about the challenges of balancing CEO responsibilities with parenting, particularly as a single mother. She has advocated for workplace policies supporting working parents and particularly working mothers.

Controversies

Beyond the FDA battle, Wojcicki and 23andMe have faced several controversies:

Privacy Concerns: Critics worry that genetic databases represent privacy risks, potentially used by insurance companies, law enforcement, or other entities to discriminate or surveil. While 23andMe maintains customer data is protected, high-profile genetic privacy breaches elsewhere have heightened concerns.

Data Monetization: The pharmaceutical partnerships have sparked accusations that 23andMe is profiting from customer DNA without adequate compensation or consent. Wojcicki argues customers explicitly agree to research uses and that advancing medical knowledge benefits everyone.

Accuracy Questions: Some customers report receiving contradictory results from different genetic testing companies, raising questions about test accuracy and interpretation.

Racial Disparities: 23andMe's database overrepresents people of European ancestry, limiting its utility for other populations and potentially exacerbating health disparities.

Data Breach (2023): In October 2023, 23andMe disclosed a data breach affecting approximately 6.9 million users. Hackers accessed genetic and ancestry information by exploiting reused passwords. The breach highlighted security vulnerabilities in genetic databases.

Net Worth

Wojcicki's net worth is estimated at approximately $800 million, primarily from her 23andMe stake. However, this figure has declined substantially from its peak given 23andMe's stock collapse. Her wealth also includes divorce settlement assets from Brin, though specific financial terms of their divorce were not publicly disclosed. Brin's net worth exceeds $120 billion, suggesting a potentially substantial settlement.

Legacy and Impact

Anne Wojcicki's ultimate legacy remains unwritten and highly dependent on 23andMe's trajectory. If the company successfully transitions to drug discovery and develops breakthrough therapies, Wojcicki will be remembered as a visionary who democratized genetic information and translated it into medical advances. If 23andMe collapses, she may be viewed as someone who built an unsustainable business model that commodified people's DNA without delivering promised value.

What seems certain is that Wojcicki helped pioneer direct-to-consumer genetic testing, making it mainstream and accessible. Millions of people have learned about their ancestry and genetic predispositions because of 23andMe. Whether this represents genuine medical progress or expensive entertainment remains debated.

References

External Links

23andMe Official Website